Margaret Dugan, M.D., joined our Board of Directors in February 2022.

Dr. Dugan has served as Chief Medical Officer of Dracen Pharmaceuticals since 2018. Prior to that, she was Senior Vice President at Novartis Oncology, responsible for global strategic drug development and portfolio management, including translational science, early- and late-stage clinical development, life cycle management and companion diagnostic development that resulted in several regulatory filings and approvals. For five years, Dr. Dugan led the Novartis Exploratory Oncology Development Group, which transitioned compounds from discovery to proof-of-concept in the clinic, and has also held several development positions at Schering-Plough (now Merck & Co.) and American Cyanamid (now Pfizer).

Dr. Dugan received her B.A. and M.D. and training in hematology and oncology from New York University.